Antimicrobial therapy
Methods and compositions comprising hogocidin peptides (SH-lantibiotics), derivatives and variants are provided. Also provided are methods and compositions comprising probiotic compositions utilizing strains of S. hominis and S. epidermidis that produce hogocidin, hogocidin-like peptides, or other inhibitors of skin pathogens. Methods of treatment for microbial skin infections and atopic dermatitis are also provided.
1. A method of treating a skin disease or disorder, comprising contacting a subject having a skin disease or disorder with an effective amount of a composition comprising one or more probiotic bacteria, wherein the one or more probiotic bacteria comprises one or more coagulase-negative bacterial strains of the genus Staphylococcus, wherein the one or more probiotic bacteria produces a peptide comprising the sequence of SEQ ID NO:56 or SEQ ID NO:57 .
2. The method of claim 1 , wherein the peptide comprises one or more D-amino acids or non-naturally occurring amino acids.
3. The method of claim 1 , wherein the one or more probiotic bacteria have been amplified in an appropriate culture medium and are present in said composition at a concentration of at least 10 3 CFU/gram.
4. The method of claim 1 , wherein the one or more probiotic bacteria comprise Staphylococcus epidermidis, Staphylococcus hominis or a combination of Staphylococcus epidermidis and Staphylococcus hominis.
5. The method of claim 1 , wherein the one or more probiotic bacteria comprise Staphylococcus hominis strains A9, C2, AMT2, AMT3, AMT4-C2, AMT4-G1, AMT4-D12, or any combination thereof.
6. The method of claim 1 , wherein the one or more probiotic bacteria comprise Staphylococcus epidermidis strains MO34, MO38, A11, AMT1, AMT5-C5, AMT5-G6, or any combination thereof.
7. The method of claim 1 , wherein the one or more probiotic bacteria demonstrate a Fatty Acid Methyl Ester profile having peaks at any three or more of 0.700, 0.711, 1.742, 2.017, 2.122, 2.313, 2.341, 2.623, 2.686, 2.737, 2.937, 2.967, 3.052, 3.250, 3.286, 3.299, 3.319, 3.364, 3.559, 3.590, 3.670, 3.806, 3.899, 3.925, and 3.969 minutes.
8. The method of claim 1 , wherein the contacting comprises topical administration.
9. The method of claim 1 , wherein the composition is formulated for topical administration.
10. The method of claim 1 , wherein the composition comprises a prebiotic compound, a protectant, humectant, emollient, abrasive, salt, a surfactant, or any combination thereof.
11. The method of claim 1 , wherein the composition is formulated as a cream, ointment, unguent, spray, powder, oil, thickened formulation, or poultice.
12. The method of claim 1 , wherein the one or more probiotic bacteria is provided in a live form.
13. The method of claim 1 , wherein the one or more probiotic bacteria is provided in a lyophilized form, a freeze-dried form, a spray dried form, or any combination thereof.
14. The method of claim 13 , wherein the one or more probiotic bacteria can be reconstituted into a live form.
15. The method of claim 1 , wherein the composition further comprises a cathelicidin peptide, derivative or variant.
16. The method of claim 1 , further comprising contacting the subject with a cathelicidin peptide, derivative or variant.
17. The method of claim 1 , wherein the skin disease or disorder comprises Staphylococcus aureus infection, colonization, or both.
18. The method of claim 1 , wherein the skin disease or disorder comprises dysbiosis of the skin, scalp, mucosae, or any combination thereof.
19. The method of claim 1 , the method comprising, prior to the contacting step, identifying a subject with dysbiosis of the skin, scalp, mucosae, or any combination thereof.
20. The method of claim 1 , wherein the skin disease or disorder comprises a skin infection, a skin colonization, a mucosal infection, a mucosal colonization, folliculitis, atopic dermatitis, psoriasis, mastitis, acne, or any combination thereof.